Endometrial cancer medical therapy
|
Endometrial cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Endometrial cancer medical therapy |
|
Risk calculators and risk factors for Endometrial cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Stage III endometrial cancer
- Patients with stage III endometrial cancer are treated with surgery, followed by chemotherapy, or radiation therapy, or both.
- Patients with inoperable disease caused by tumor that extends to the pelvic wall may be treated with a combination of chemotherapy and radiation therapy. The usual approach is to use a combination of intracavitary radiation therapy and external-beam radiation therapy.
- Clinical trials
- 1. In a trial conducted in a subset of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement, the use of the combination of cisplatin and doxorubicin resulted in improved overall survival (OS) compared with whole-abdominal radiation therapy (adjusted hazard ratio, 0.68; 95% confidence interval limits, 0.52–0.89;P = .02; 5-year survival rates of 55% vs. 42%).[Level of evidence: 1iiA]
- 2.The three-drug regimen (doxorubicin, cisplatin, and paclitaxel) with granulocyte colony-stimulating factor (G-CSF), was significantly superior to cisplatin plus doxorubicin: response rates were 57% versus 34%; progression-free survival was 8.3 months versus 5.3 months; and overall survival (OS) was 15.3 months versus 12.3 months.
Stage IV endometrial cancer
- Treatment of patients with stage IV endometrial cancer is dictated by the site of metastatic disease and symptoms related to disease sites. For bulky pelvic disease, radiation therapy consisting of a combination of intracavitary and external-beam radiation therapy is used.
- Clinical Trials
- several randomized trials have confirmed improved survival when adjuvant chemotherapy is used instead of radiation therapy.
- 1. In a trial conducted in a subset of patients with stage III or IV disease with residual tumors smaller than 2 cm and no parenchymal organ involvement, the use of the combination of cisplatin and doxorubicin resulted in improved overall survival (OS) compared with whole-abdominal radiation therapy (adjusted hazard ratio, 0.68; 95% confidence interval limits, 0.52–0.89;P = .02; 5-year survival rates of 55% vs. 42%).[Level of evidence: 1iiA]
- 2.The three-drug regimen (doxorubicin, cisplatin, and paclitaxel) with granulocyte colony-stimulating factor (G-CSF), was significantly superior to cisplatin plus doxorubicin: response rates were 57% versus 34%; progression-free survival was 8.3 months versus 5.3 months; and overall survival (OS) was 15.3 months versus 12.3 months.
- 3. The most common hormonal treatment has been progestational agents, which produce good antitumor responses in as many as 15% to 30% of patients. These responses are associated with significant improvement in survival. Progesterone and estrogen hormone receptors have been identified in endometrial carcinoma tissues. Responses to hormones are correlated with the presence and level of hormone receptors and the degree of tumor differentiation. Standard progestational agents include hydroxyprogesterone, medroxyprogesterone, and megestrol.
- 4. Biologic agents under evaluation for patients with advanced and recurrent endometrial cancer include:
- Bevacizumab, which was given as a single agent in a phase II trial, and the overall response rate was 13.5%.
- Bevacizumab and temsirolimus.